f-star and Boehringer Ingelheim to collaborate in discovery and development of therapeutic antibodies

24-Nov-2010 - f-star Biotechnologische Forschungs-und Entwicklungsges.m.b.H announced the signing of a collaboration and license agreement with Boehringer Ingelheim for joint discovery of new antibody-derived therapeutic products based on f-star’s Modular Antibody Technology. Under the terms of the agreement, ...

Antibody Engineering Company F-Star Buys Back Royalty Obligations

TVM Capital Joins Investor Syndicate

01-Apr-2008 - f-star announced that it has acquired future royalty obligations to New Century Pharmaceuticals (NCP) via a one-off payment. Modular Antibody Technology was originally developed by Prof. Florian Rueker, one of f-star's founders, in collaboration with NCP, a U.S. biopharmaceutical company. After ...

F-Star Opens Second Research Site in Cambridge, UK

14-Mar-2008 - f-star announced that it will open a research facility in Cambridge, UK in addition to its headquarters in Vienna, Austria. The facility will be located at the Babraham Research Campus, home to a number of biotech companies and close to the Medical Research Council's Laboratory of Molecular ...

F-Star Appoints Three Pioneers in Antibody Engineering and Development to its Newly Established Scientific Advisory Board

14-Dec-2007 - f-star announced that it has established a Scientific Advisory Board and has appointed three scientists to form the nucleus of this advisory body. Members of f-star's Scientific Advisory Board include: Professor Sir Ravinder Maini, Imperial College, London, UK Sir Ravinder Maini is Emeritus ...